Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:41 AM
Ignite Modification Date:
2025-12-25 @ 2:41 AM
NCT ID:
NCT06998433
Eligibility Criteria:
Inclusion Criteria:
* Female
* Minimum age of 18 years old
* Self-identification as person of African descent, including African, Afro-Caribbean, Afro-Latino, and/or African American
* Clinical diagnosis of mild to moderate CCCA located on the vertex or fronto-vertex scalp, and as defined by Central Hair Loss Grade stages 1B, 2B, and 3B
Exclusion Criteria:
* Intralesional or systemic anti-inflammatory medications (corticosteroids, tetracycline antibiotics, anti-malarials) or immunosuppressive drugs (cyclosporine, mycophenolate mofetil, methotrexate, azathioprine, janus kinase inhibitors) within 4 weeks of baseline visit
* Pregnant women
* Topical minoxidil, metformin, or retinoic acid for 4 weeks prior to baseline visit
* Severe or end-stage CCCA, Central Hair Loss Grade stage \>3B
* Thrombocytopenia (as defined by baseline platelet count \< 150,000 platelets per microliter of blood)
* Antiplatelet or platelet altering medications (such as but not limited to aspirin, NSAIDS, clopidogrel, ticagrelor, and prasugrel, cilostazol, and dipyridamole) within 4 weeks of baseline visit
* Diagnosis of other significant concomitant alopecia
* Clinically significant uncontrolled disease, malignancy, or major psychiatric illness requiring hospitalization (as determined by investigator)
* Subjects not willing to follow suggested hair care practices such as limiting/avoiding traction-associated styles
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT06998433
Study Brief:
Protocol Section:
NCT06998433